Vascular endothelial growth factor upregulates expression of annexin A2 in vitro and in a mouse model of ischemic retinopathy

Molecular Vision

Volumn 15, Issue , 2009, Pages 1231-1242

  Zhao, ShiHong ^a   Huang, LiNa ^a   Wu, JinHui ^a   Zhang, Yuan ^a   Pan, DongYan ^a   Liu, Xin ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOCORTIN 2; MESSENGER RNA; SMALL INTERFERING RNA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE CASSETTE; GENE EXPRESSION REGULATION; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RETINA ISCHEMIA; RETINA NEOVASCULARIZATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; ANNEXIN A2; BLOTTING, WESTERN; CELL LINE; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; INDOLES; ISCHEMIA; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; POLYMERASE CHAIN REACTION; PROPIONIC ACIDS; PROTEIN KINASE C; RECOMBINANT PROTEINS; RETINAL DISEASES; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; RNA, SMALL INTERFERING; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 67650067208     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Iranmanesh R, Eandi CM, Peiretti E, Klais CM, Garuti S, Goldberg DE, Slakter JS, Yannuzzi LA. The nature and frequency of neovascular age-related macular degeneration. Eur J Ophthalmol 2007; 17:75-83.
2. Das A, McGuire PG. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res 2003; 22:721-48.
3. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 2003; 48:257-93.
4. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353-64.
5. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-76.
6. Boccellino M, Giovane A, Servillo L, Balestrieri C, Quagliuolo L. Fatty acid mobilized by the vascular endothelial growth factor in human endothelial cells. Lipids 2002; 37:1047-52.
7. Gerke V, Moss SE. Annexins: from structure to function. Physiol Rev 2002; 82:331-71.
8. Rescher U, Gerke V. Annexins-unique membrane binding proteins with diverse functions. J Cell Sci 2004; 117:2631-9.
9. Ferrara N. Vascular Endothelial Growth Factor: Basic Science and Clinical Progress. Endocr Rev 2004; 25:581-611.
10. Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L. VEGF-receptor signal transduction. Trends Biochem Sci 2003; 28:488-94.
11. Sharma MC, Sharma M. The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target. Curr Pharm Des 2007; 13:3568-75.
12. Sharma MR, Koltowski L, Ownbey RT, Tuszynski GP, Sharma MC. Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol 2006; 81:146-56.
13. Syed SP, Martin AM, Haupt HM, Arenas-Elliot CP, Brooks JJ. Angiostatin receptor annexin II in vascular tumors including angiosarcoma. Hum Pathol 2007; 38:508-13.
14. Ottino P, Finley J, Rojo E, Ottlecz A, Lambrou GN, Bazan HEP, Bazan NG. Hypoxia activates matrix metalloproteinase expression and the VEGF system in monkey choroid-retinal endothelial cells: Involvement of cytosolic phospholipase A2 activity. Mol Vis 2004; 10:341-50.
15. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, D'Amore PA. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994; 35:101-11.
16. D'Amore PA. Mechanisms of retinal and choroidal neovascularization. Invest Ophthalmol Vis Sci 1994; 35:3974-9.
17. Aiello LP. Clinical implications of vascular growth factors in proliferative retinopathies. Curr Opin Ophthalmol 1997; 8:19-31.
18. Tong JP, Yao YF. Contribution of VEGF and PEDF to choroidal angiogenesis: a need for balanced expressions. Clin Biochem 2006; 39:267-76.
19. Ohno-Matsui K. Molecular mechanism for choroidal neovascularization in age-related macular degeneration. Nippon Ganka Gakkai Zasshi 2003; 107:657-73.
20. Perez-Pinera P, Berenson JR, Deuel TF. Pleiotrophin, a multifunctional angiogenic factor: mechanisms and pathways in normal and pathological angiogenesis. Curr Opin Hematol 2008; 15:210-4.
21. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27-31.
22. Benedetta Donati M, Gozdzikiewicz J. Angiogenesis and the progress of vascular and tumor biology: A tribute to Judah Folkman. Thromb Haemost 2008; 99:647-50.
23. Hayes MJ, Longbottom RE, Evans MA, Moss SE. Annexinopathies. Subcell Biochem 2007; 45:1-28.
24. Moses MA. The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells 1997; 15:180-9.
25. Berglin L, Sarman S, van der Ploeg I, Steen B, Ming Y, Itohara S, Seregard S, Kvanta A. Reduced choroidal neovascular membrane formation in matrix metalloproteinase-2-deficient mice. Invest Ophthalmol Vis Sci 2003; 44:403-8.
26. Hwang J, Hodis HN, Hsiai TK, Asatryan L, Sevanian A. Role of annexin II in estrogen-induced macrophage matrix metalloproteinase-9 activity: the modulating effect of statins. Atherosclerosis 2006; 189:76-82.
27. Nezi L, Greco D, Nitsch L, Garbi C. The role of proteases in fibronectin matrix remodeling in thyroid epithelial cell monolayer cultures. Biol Chem 2002; 383:167-76.
28. Haas TL. Endothelial cell regulation of matrix metalloproteinases. Can J Physiol Pharmacol 2005; 83:1-7.
29. Babbin BA, Parkos CA, Mandell KJ, Winfree LM, Laur O, Ivanov AI, Nusrat A. Annexin 2 regulates intestinal epithelial cell spreading and wound closure through Rho-related signaling. Am J Pathol 2007; 170:951-66.
30. Garver WS, Hossain GS, Winscott MM, Heidenreich RA. The Npc1 mutation causes an altered expression of caveolin-1, annexin II and protein kinases and phosphorylation of caveolin-1 and annexin II in murine livers. Biochim Biophys Acta 1999; 1453:193-206.
31. Yan G, Luo W, Lu Z, Luo X, Li L, Liu S, Liu Y, Tang M, Dong Z, Cao Y. Epstein-Barr virus latent membrane protein 1 mediates phosphorylation and nuclear translocation of annexin A2 by activating PKC pathway. Cell Signal 2007; 19:341-8.
32. Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, Robinson GS, Takagi H, Newsome WP, Jirousek MR, King GL. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996; 98:2018-26.
33. Chiang Y, Rizzino A, Sibenaller ZA, Wold MS, Vishwanatha JK. Specific down-regulation of annexin II expression in human cells interferes with cell proliferation. Mol Cell Biochem 1999; 199:139-47.
34. Wolberg AS, Roubey RA. Annexin A2: better left alone. Blood 2005; 105:1845-6.
35. Zhang J, McCrae KR. Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. Blood 2005; 105:1964-9.
36. Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, Kurihara T, Darland DC, Young MJ, D'Amore PA. Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors. PLoS One 2008; 3:e3554.
37. Stalmans I. Role of the vascular endothelial growth factor isoforms in retinal angiogenesis and DiGeorge syndrome. Verh K Acad Geneeskd Belg 2005; 67:229-76.
38. Swisher JF, Khatri U, Feldman GM. Annexin A2 is a soluble mediator of macrophage activation. J Leukoc Biol 2007; 82:1174-84.